Skip to main content

Table 3 Multivariate analysis

From: Safety and clinical outcomes of remdesivir in hospitalised COVID-19 patients: a retrospective analysis of active surveillance database

Variables Odds ratio 95% Confidence interval p-value Adjusted odds ratio 95% Confidence interval p-value
Age group (years)
 20–40 1.00      
 40–60 1.51 (0.78, 2.94) 0.222    
 ≥ 60 2.99 (1.56, 5.73) 0.001    
Gender
 Male 1.54 (0.99, 2.40) 0.062    
 Female 1.00      
Co-morbidities
 Hypertension (Yes/No) 0.71 (0.45, 1.13) 0.146    
 Diabetes (Yes/No) 1.93 (1.36, 2.75) 0.000 1.55 (1 01, 2.39) 0.05
 Lung disease (Yes/No) 1.85 (0.96, 3.56) 0.063    
 Cardiac (Yes/No) 2.57 (1.52, 4.33) 0.000 3.76 (1.95, 7.25) < 0.001
Type of oxygen support
 SLFO 1.00      
 HFO 2.74 (1.55, 4.83) 0.000 2.35 (1.26, 4.32) 0.007
 NIV 10.37 (6.29, 17.10) 0.000 11.04 (6.4, 18.9) < 0.001
 MV 36.25 (20.14, 65.23) 0.000 40.51 (21.010, 77.7) < 0.001
Remdesivir treatment duration
 < 5 days 1      
 5 days 0.28 (0.19, 0.41) < 0.001 0.29 (0.19, 0.45) < 0.001
 ≥ 6 days 0.39 (0.21, 0.72) 0.002 0.40 (0.20, 0.80) 0.009
Concomitant medications
 Steroids 1      
 Others 1.08 (0.69, 1.69) 0.735    
  1. SLFO standard low-flow oxygen, HFO high-flow oxygen, NIV non-invasive ventilation, MV mechanical ventilation